Abstract
Aim: To determine if additional 18F-sodium fluoride PET/CT (NaF-PET/CT) improves the prognostic accuracy in the initial staging of prostate cancer patients with normal bone scintigraphy undergoing prostatectomy. Methods: A prospective cohort study examined NaF-PET/CT in intermediate- or high-risk prostate cancer with negative bone scintigraphy who were scheduled for prostatectomy. Biochemical response: PSA levels<0.2 ng/mL at six weeks and six months postoperatively, PSA level≥0.2 ng/mL was biochemical failure. Results: Eighty-one patients were included in the study; seventy-five patients (93%) achieved biochemical responses, six patients had biochemical failure. NaF-PET/CT indicated bone metastasis in one patient (1.2%), was equivocal in seven patients (8.6%), without bone metastases in 73 patients (90.1%). Eight patients with bone metastases or equivocal results on NaF-PET/CT exhibited biochemical responses. All patients with biochemical failure had negative NaF-PET/CT and bone scintigraphy for bone metastases. Conclusion: NaF-PET/CT has no added value for bone staging in intermediate- and high-risk prostate cancer patients with normal bone scintigraphy results undergoing prostatectomy.
- Oncology: GU
- PET/CT
- SPECT/CT
- 18F-sodium fluoride PET/CT
- bone scintigraphy
- prostate cancer
- radical prostatectomy
- Copyright © 2019 by the Society of Nuclear Medicine and Molecular Imaging, Inc.